Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
ELEVAI Labs Inc. ( (ELAB) ) has provided an announcement.
On February 18, 2025, Northstrive Biosciences announced the successful submission of a pre-Investigational New Drug (pre-IND) meeting request to the U.S. Food and Drug Administration for EL-22, a pioneering obesity therapy aimed at fat loss and muscle preservation. The company is seeking FDA guidance on its nonclinical studies and clinical development plans for combining EL-22 with GLP-1 receptor agonists, with a meeting expected in the second fiscal quarter of 2025. This development could significantly impact Northstrive’s market positioning as it lays the groundwork for further clinical trials necessary for EL-22’s regulatory approval and commercial availability.
More about ELEVAI Labs Inc.
Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., is a biopharmaceutical company focused on developing and acquiring innovative aesthetic medicines. Its primary asset, EL-22, employs an engineered probiotic approach to address muscle preservation in obesity treatments, including GLP-1 receptor agonists.
YTD Price Performance: -33.06%
Average Trading Volume: 2,405,394
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $6.71M
Learn more about ELAB stock on TipRanks’ Stock Analysis page.
